Astellas Pharma Inc. (4503)

Overview

Astellas Pharma Inc. is a global pharmaceutical company with a rich history dating back to 1923. Based in Tokyo, Japan, Astellas engages in the manufacturing, marketing, import, and export of innovative pharmaceutical solutions. With a commitment to improving the health of people worldwide, the company’s efforts are focused on developing medicines that address critical areas of medical need. Astellas has built a strong reputation through its extensive portfolio of products, particularly in oncology, urology, immunology, and nephrology. It also emphasizes research collaborations and partnerships, as seen in its agreements with Vivtex Corporation for drug formulation technologies and with Roche Diabetes Care Japan for diabetes management solutions, to bolster its product development and commercialization capabilities.

Products and Services

• XTANDI: An innovative treatment for prostate cancer, offering hope to patients battling this prevalent form of cancer. XTANDI has been a crucial product in Astellas's oncology portfolio, demonstrating the company’s commitment to addressing hard-to-treat cancers.
• XOSPATA: A targeted therapy for patients with relapsed or refractory acute myeloid leukemia (AML) characterized by a FLT3 mutation. XOSPATA embodies Astellas's focus on precision medicine, providing a lifeline to a specific subset of AML patients.
• PADCEV: A treatment option for patients with metastatic urothelial cancer, especially those who have limited treatment options. PADCEV signifies Astellas's innovation in the field of urology and oncology.
• Evrenzo: Addresses anemia associated with chronic kidney disease (CKD), offering an alternative to traditional anemia treatments. Evrenzo is part of Astellas's endeavor to improve the quality of life for patients with CKD.
• Betanis/Myrabetriq/BETMIGA: A versatile treatment for overactive bladder, providing relief to patients suffering from this uncomfortable and often debilitating condition. This product highlights Astellas’s commitment to addressing everyday health challenges.
• Prograf and Advagraf/Graceptor/ASTAGRAF XL: Key immunosuppressants that play a critical role in the success of organ transplants. These products ensure that patients undergoing transplants can achieve and maintain the delicate balance required for organ acceptance.

In addition to these products, Astellas also engages in meaningful research collaborations and partnerships aimed at enhancing its product offerings. For instance, its collaboration with Vivtex Corporation aims to develop novel oral formulations of therapeutic candidates, while its partnership with Roche Diabetes Care Japan focuses on creating integrated solutions for diabetes self-management. These initiatives underscore Astellas’s dedication to innovation and patient care in the pharmaceutical industry.